CRISPR, Sirius Announce Strategic siRNA Therapy Partnership US, China

CRISPR Therapeutics and Sirius Therapeutics have entered a strategic partnership to develop and commercialize siRNA therapies, focusing initially on SRSD107, a next-generation anticoagulant targeting Factor XI to reduce thrombotic events with minimal bleeding risk. Under the agreement, CRISPR will pay Sirius $25 million upfront in cash and $70 million in equity, and the companies will share costs and profits equally, with CRISPR leading commercialization in the U.S. and Sirius in Greater China. SRSD107 has shown promising Phase 1 trial results, including significant reductions in Factor XI activity and sustained efficacy, and is moving toward Phase 2 trials for venous thromboembolism prevention. CRISPR also retains the option to nominate and fund up to two additional siRNA targets, with rights to lead clinical development and commercialization, while Sirius is eligible for milestone payments and tiered royalties. This collaboration aligns with CRISPR's broader gene-editing efforts and positions both companies to address unmet needs in thromboembolic disorders, with SRSD107 potentially offering a differentiated treatment compared to existing therapies. Despite financial challenges reflected in CRISPR's stock performance, the deal leverages CRISPR's strong balance sheet and Sirius's siRNA expertise to advance innovative therapies in a significant market.